Clinical trials: Emergency Treatment
- Condition Emergency Treatment
- Funder type Industry (pharma, biotech, devices)
- Age group Children (under 18)
Ebola Virus Disease
R3470-3471-3479 (REGN-EB3) Expanded Access Protocol (EAP) for Treatment of Ebola Virus Disease
Provide access to REGN-EB3 for the treatment of patients with Ebola Virus Disease (EVD).
- Trial name
- NCT03576690
- Testing
- REGN3470-3471-3479
- Sponsor
- Regeneron Pharmaceuticals
Dehydration
Efficacy and Time and Resources for Hylenex-facilitated SC Rehydration Versus ORT for Dehydrated Children in the Emergency Department (ED)
The purpose is to evaluate the safety and efficacy as well as the time and resources needed in the ED setting to achieve rehydration in young pediatric subjects with mild to moderate dehydration using hylenex-facilitated SC…
- Trial name
- INFUSE-TM (NCT01120431)
- Testing
- Oral rehydration fluid, Isotonic hydration fluid and recombinant human hyaluronidase
- Sponsor
- Baxter Healthcare Corporation
Acute Pain Due to Trauma
Efficacy and Safety of Methoxyflurane (Penthrox) for the Treatment of Acute Pain in Minor Trauma
This study investigates the treatment of acute pain, an unpleasant feeling caused by an injury. The overall purpose of the study is to gain more information that the pain relief medicine Penthrox(Methoxyflurane) administered…
- Trial name
- STOP! (NCT01420159)
- Testing
- Methoxyflurane
- Where
- 6 sites in United Kingdom
- Volunteers
- 300 people
- Sponsor
- Medical Developments International Limited
Dehydration
Study of Subcutaneous Rehydration With Recombinant Human Hyaluronidase for Infants and Children
The aim of the study is to evaluate the safety, effectiveness and ease of use of subcutaneous (SC) rehydration using HYLENEX-augmented SC infusion of fluids and electrolytes for the rehydration of pediatric patients with mild to…
- Trial name
- INFUSE-PR (NCT00477152)
- Testing
- hyaluronidase (human recombinant)/rehydration fluid
- Volunteers
- 52 people
- Sponsor
- Baxter Healthcare Corporation
Schizophrenia, Psychotic Disorders
A Study of Risperidone in Combination With Lorazepam Compared With Standard Therapy for Emergency Treatment of Schizophrenic Patients
The purpose of the study is to show that risperidone (an antipsychotic medication) combined with lorazepam (an anti-anxiety medication) is more effective than conventional therapy administered by intramuscular injection for…
- Conditions
- Schizophrenia, Psychotic Disorders, Emergency Treatment
- Trial name
- NCT00249171
- Testing
- risperidone
- Volunteers
- 226 people
- Sponsor
- Janssen Pharmaceutica N.V., Belgium
Mycoses
Single Patient Treatment of Posaconazole in Invasive Fungal Infections (Study P05113)
The purpose of this study is to provide posaconazole compassionate treatment to patients with invasive fungal infections: 1) which are resistant to standard antifungal therapies; 2) for which there are no effective therapies; 3)…
- Trial name
- NCT00686621
- Testing
- Posaconazole
- Sponsor
- Merck Sharp & Dohme LLC
Respiratory Disorder, Diabetes
The Measurement of VItal SIgns by Lifelight® Software in comparisON to the Standard of Care - Multi-site Development
AIM: To advance the development and accuracy of the Lifelight® app for the measurement of vital signs, therefore developing a non-invasive and easy-to-perform means of measuring vital signs which can be implemented across a wide…
- Conditions
- Respiratory Disorder, Diabetes, Cardiovascular Diseases, Critical Care
- Trial name
- VISION-MD (NCT04763746)
- Testing
- Lifelight Data Collect Sub-protocol 1, Lifelight Data Collect Sub-protocol 2, Lifelight Data Collect Sub-protocol 3
- Where
- United Kingdom
- Volunteers
- 1,869 people, healthy volunteers welcome
- Sponsor
- Xim Limited
Sudden Cardiac Arrest, Emergency Care
Tempus Pro Monitor Registry
A multicenter, prospective and retrospective, observational, post market study.
- Trial name
- NCT05587764
- Testing
- Standard of Care
- Where
- United States
- Volunteers
- 103 people
- Sponsor
- Heartstream US LLC
Acute Liver Failure
Emergency Use of OCR-002 in Acute Liver Failure (ALF)
This study provides emergency use of the unapproved study medication in ALF patients with acute liver failure who are not responding to standard of care.
- Trial name
- NCT01634230
- Testing
- OCR-002
- Where
- United States
- Sponsor
- Ocera Therapeutics, Inc.
Compliance, Emergency Department Aftercare
Using Point-of-Care Video Prescriptions to Improve Aftercare Following Discharge From a Pediatric Emergency Department
The goal of this project is to develop the content and delivery platform that electronically distributes mobile video discharge education for underserved populations and to demonstrate utilization, satisfaction, and improved…
- Conditions
- Compliance, Emergency Department Aftercare, Emergency Department Utilization
- Trial name
- NCT01543438
- Testing
- Video Prescription (additional education)
- Where
- United States
- Volunteers
- 5,000 people, healthy volunteers welcome
- Sponsor
- healthEworks LLC
Pain, Acute
Methoxyflurane Analgesia for Paediatric Injuries
This is a randomised, double-blind, multicentre, placebo controlled study to evaluate the safety and efficacy of methoxyflurane (Penthrox®) for the treatment of acute pain in children and adolescents from 6 to less than 18 years…
- Trial name
- MAGPIE (NCT03215056)
- Testing
- Methoxyflurane, Normal saline
- Where
- 11 sites in Ireland, United Kingdom
- Volunteers
- 192 people
- Sponsor
- Medical Developments International Limited
COVID-19
Expanded Access Program to Provide Bamlanivimab (LY3819253) for the Treatment of COVID-19
The treating physician/investigator contacts Lilly when, based on their medical opinion, a patient meets the criteria for inclusion in the expanded access program.
- Trial name
- NCT04603651
- Testing
- Bamlanivimab
- Sponsor
- Eli Lilly and Company
Protein C Deficiency
Retrospective Study to Capture Dosing and Treatment Outcome Data in Participants With Severe Congenital Protein C Deficiency Who Were Treated With Protein C Concentrate Under an Emergency Use IND
This is a data collection study with the purpose of capturing dosing and treatment outcome data in participants with severe congenital protein C deficiency who were treated with protein C concentrate under an Emergency Use…
- Trial name
- NCT00161720
- Testing
- Protein C Concentrate (Human) Vapor Heated
- Where
- 10 sites in United States
- Volunteers
- 11 people
- Sponsor
- Baxalta now part of Shire
Bacterial Infections
Study Evaluating Emergency-use Tigecycline in Subjects With Resistant Pathogens.
The purpose of this study is to provide a mechanism for the emergency use of tigecycline in the appropriate clinical situations.
- Trial name
- NCT00205816
- Testing
- Tigecycline
- Where
- 3 sites in Germany, Poland
- Volunteers
- 26 people
- Sponsor
- Wyeth is now a wholly owned subsidiary of Pfizer
Von Willebrand Disease
A Study of Recombinant Von Willebrand Factor (rVWF) With or Without ADVATE in Children With Severe Von Willebrand Disease (VWD)
The main aim of the study is to check effectiveness, side effects, and tolerability of vonicog alfa (recombinant von Willebrand factor [rVWF]), with or without ADVATE, in the treatment and control of nonsurgical bleeding events…
- Trial name
- NCT02932618
- Testing
- Vonicog alfa, Antihemophilic Factor (Recombinant)
- Where
- 46 sites in United States, Austria and 11 more
- Volunteers
- 47 people
- Sponsor
- Baxalta now part of Shire
Leber's Hereditary Optic Neuropathy
Emergency Administration of EPI-743 to a Single Patient With Leber's Hereditary Optic Neuropathy [LHON]
Expanded access Protocol to treat LHON subjects with EPI743
- Trial name
- NCT02300753
- Testing
- EPI-743
- Where
- United States
- Sponsor
- Edison Pharmaceuticals Inc
COVID-19
Expanded Access Program of Ruxolitinib for the Emergency Treatment of Cytokine Storm From COVID-19 Infection
To provide ruxolitinib through an expanded access program for the treatment of cytokine storm due to COVID-19 in the United States to patients who are eligible but not able to be hospitalized or who are hospitalized with a…
- Trial name
- NCT04355793
- Testing
- Ruxolitinib
- Sponsor
- Incyte Corporation